Top Story
Spencer develops metformin for diabetics without GI side effects
Those who suffer from Type 2 diabetes know that the treatment can feel worse than the disease. The most debilitating side-effect, and one that often presents a major barrier to patient compliance, is the nausea associated with metformin, the most popular anti-diabetic drug for glycemia control. The solution, according to Boston-based Spencer Pharmaceutical, is a better controlled-release product that does not "swell" inside the GI tract, causing gastrointestinal issues. Report
Latest News
Also Noted
> The FDA has granted priority review status for Iluvien, a sustained drug delivery system to treat diabetic macular edema. Iluvien was designed by Watertown, MA-based pSivida and licensed to Alimera Sciences based in Alpharetta, GA. Report
> The Institute of Nanotechnology and Cranfield University in the United Kingdom will present a one-day short course, "Nanotechnology for drug delivery," in association with Pharmidex, on Sept. 30. Event
> Using carbon nanotubes to delivery siRNA. Abstract
> Coming attractions from the FDA: New guidance and consensus standards on nanotechnology as part of its 2011 Nanotechnology Regulatory Science Initiative. Bulletin
Read more >>Press Releases
- Cellerant Therapeutics Awarded $153 Million Contract by Biomedical Advanced Research and Development Authority (BARDA) to Develo
- Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC
- Flagship Biosciences LLC Creates Scientific Advisory Board
- EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors
- Synexus Welcomes a New Chief Executive and Gears up for Its Next Phase of Growth
- Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer
Latest Comments
- HI John Carroll / Maureen Martino How coul...
- Obviously and absolutely, logically flawless!...
- I don't understand why Wyeth-Pfizer won the t...
- If GSK is abandoning neuroscience research, c...
- What about Susan Molineaux who just led Prote...
- Thank you for highlighting these most impress...
- That's odd. The article doesn't once mention ...
Report
Otonomy attracts money, buzz with delivery tech
There was a great deal of reporting this week on San Diego-based Otonomy closing $38.5 million in Series B financing to develop treatments related to balance disorders and hearing loss. But, as Xconomy's Luke Timmerman pointed out back in June, "The company's lead drug candidate isn't a radical sort of thing built on gee-whiz molecular biology." Report
